Valneva SE (VALN) Non-Current Deferred Tax Liability (2019 - 2026)

Valneva SE (VALN) posted Non-Current Deferred Tax Liability of $5.2 million for Q1 2026, up 1.05% sequentially from $5.1 million in Q4 2025, and up 19.33% YoY from $4.3 million in Q1 2025.

Valneva SE (VALN) Non-Current Deferred Tax Liability (2019 - 2026) Analysis & Trends

Valneva SE has reported Non-Current Deferred Tax Liability for 8 years, with the latest figure at $5.2 million in Q1 2026.

  • Quarterly Non-Current Deferred Tax Liability rose 19.33% year-over-year to $5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.2 million (up 19.33% YoY) and the FY2025 annual result came in at $5.1 million, up 13.93% from the prior year.
  • Non-Current Deferred Tax Liability advanced to $5.2 million in Q1 2026 per VALN's latest filing, from $5.1 million in the prior quarter.
  • Over five years, Non-Current Deferred Tax Liability peaked at $14.0 million in Q4 2023 and troughed at $708051.7 in Q4 2022.
  • A 5-year average of $3.8 million and a median of $4.0 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
  • The sharpest annual moves came in 2023 and 2024: Non-Current Deferred Tax Liability soared 1870.44% in 2023, then slumped 68.12% in 2024.
  • Over 5 years, Non-Current Deferred Tax Liability stood at $708051.7 in 2022, then jumped by 1870.44% to $14.0 million in 2023, then plunged by 68.12% to $4.4 million in 2024, then gained by 15.4% to $5.1 million in 2025, then advanced by 1.05% to $5.2 million in 2026.
  • According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $5.2 million, $5.1 million, and $4.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Valneva SE 618.67 Mn 477.41 Mn 1.86 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 5.19 Mn
Jun 30, 2026 5.19 Mn
Mar 31, 2026 5.19 Mn
Mar 31, 2026 5.19 Mn
Dec 31, 2025 5.13 Mn
Dec 31, 2025 5.13 Mn
Sep 30, 2025 4.62 Mn
Sep 30, 2025 4.62 Mn
Jun 30, 2025 4.57 Mn
Jun 30, 2025 4.57 Mn
Mar 31, 2025 4.35 Mn
Mar 31, 2025 4.35 Mn
Dec 31, 2024 4.45 Mn
Dec 31, 2024 4.45 Mn
Sep 30, 2024 4.16 Mn
Sep 30, 2024 4.16 Mn
Jun 30, 2024 4.03 Mn
Jun 30, 2024 4.03 Mn
Mar 31, 2024 4.02 Mn
Mar 31, 2024 4.02 Mn